425 related articles for article (PubMed ID: 35321955)
21. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
22. Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy.
Park H; Yoon EL; Kim M; Cho S; Nah EH; Jun DW
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1041-1049.e3. PubMed ID: 35504562
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease.
Pisetta C; Chillè C; Pelizzari G; Pigozzi MG; Salvetti M; Paini A; Muiesan ML; De Ciuceis C; Ricci C; Rizzoni D
High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):321-330. PubMed ID: 32436128
[TBL] [Abstract][Full Text] [Related]
24. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
[TBL] [Abstract][Full Text] [Related]
25. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
26. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
Nguyen VH; Le MH; Cheung RC; Nguyen MH
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
[TBL] [Abstract][Full Text] [Related]
27. Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease.
Lu C; Chen Y; Zhang Y; Zhao X
Diabetes Metab Syndr Obes; 2023; 16():2627-2637. PubMed ID: 37663203
[TBL] [Abstract][Full Text] [Related]
28. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
[TBL] [Abstract][Full Text] [Related]
29. The relationship between skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease subtypes in middle-aged and elderly population: a single-center retrospective study.
Xing M; Ni Y; Zhang Y; Zhao X; Yu X
Front Nutr; 2023; 10():1246157. PubMed ID: 38024359
[TBL] [Abstract][Full Text] [Related]
30. Metabolic-Associated Fatty Liver Disease (MAFLD) is associated with immune activation, increased epicardial fat volume, and steatohepatitis among people with HIV in a Thai cohort.
Han WM; Apornpong T; Chattranukulchai P; Siwamogsatham S; Lwin HMS; Boonrungsirisap J; Wichiansan T; Gatechompol S; Ubolyam S; Kerr SJ; Tangkijvanich P; Avihingsanon A
HIV Med; 2023 Sep; 24(9):1000-1012. PubMed ID: 37165782
[TBL] [Abstract][Full Text] [Related]
31. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
[TBL] [Abstract][Full Text] [Related]
32. Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction-associated fatty liver disease.
Choi KY; Kim TY; Chon YE; Kim MN; Lee JH; Hwang SG; Lee J; Kwak MK; Hong EG; Choi YM; Ha Y
J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2747-2756. PubMed ID: 37881112
[TBL] [Abstract][Full Text] [Related]
33. Association of low muscle strength with metabolic dysfunction-associated fatty liver disease: A nationwide study.
Lee GB; Huh Y; Lee SH; Han B; Kim YH; Kim DH; Kim SM; Choi YS; Cho KH; Nam GE
World J Gastroenterol; 2023 Dec; 29(45):5962-5973. PubMed ID: 38131000
[TBL] [Abstract][Full Text] [Related]
34. Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease.
Liu J; Lv H; Wang J; Zhu Q; Chen G; Jiang Y; Zhao K; Shao L; Shi J; Pan X
Ann Hepatol; 2023; 28(2):100892. PubMed ID: 36577468
[TBL] [Abstract][Full Text] [Related]
35. "Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV".
Cervo A; Sebastiani G; Milic J; Krahn T; Mazzola S; Petta S; Cascio A; Guaraldi G; Mazzola G
HIV Med; 2022 Sep; 23(8):911-921. PubMed ID: 35199429
[TBL] [Abstract][Full Text] [Related]
36. Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease from clinical to pathological characteristics: a multi-center cross-sectional study in real world.
Li Y; Dai C; Ruan Y; Yang H; Zeng H; Huang R; Wang J; Dai M; Hao J; Wang L; Li J; Yan X; Lu Z; Ji F
Postgrad Med J; 2024 Apr; 100(1183):319-326. PubMed ID: 38272486
[TBL] [Abstract][Full Text] [Related]
37. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
[TBL] [Abstract][Full Text] [Related]
38. Associations of urinary organophosphate esters metabolites and diet quality with nonalcoholic/metabolic dysfunction-associated fatty liver diseases in adults.
Aimuzi R; Xie Z; Qu Y; Jiang Y; Luo K
Ecotoxicol Environ Saf; 2023 Apr; 254():114720. PubMed ID: 36889207
[TBL] [Abstract][Full Text] [Related]
39. Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study.
Zhao Q; Yin Y; Deng Y
Nutr Diabetes; 2023 Nov; 13(1):21. PubMed ID: 37968264
[TBL] [Abstract][Full Text] [Related]
40. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
Lee H; Lee YH; Kim SU; Kim HC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
